Oblimersen: all 38 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal MelanomaTerminatedNCT01200342Phase 2Results posted
• Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaTerminatedNCT00736450Early Phase 1Results posted
• A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerTerminatedNCT00064259Phase 1/2Results posted
• Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedNCT00063934Phase 1/2Results posted
• Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
• Genasense as a 2-hour Intravenous Infusion in Subjects With Solid TumorsCompletedNCT00636545Phase 1
• A Phase I Study of G3139 Subcutaneous in Solid TumorsCompletedNCT00543231Phase 1
• Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic ImpairmentTerminatedNCT00543205Phase 2/3
• Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal FunctionCompletedNCT00543075Phase 1
• Trial of Dacarbazine With or Without Genasense in Advanced MelanomaCompletedNCT00518895Phase 3
• This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)WithdrawnNCT00517218Phase 3
• Abraxane and Temodar Plus Genasense in Advanced MelanomaStatus unknownNCT00409383Phase 1
• Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
• Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedNCT00091078Phase 2
• Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
• Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the ProstateCompletedNCT00085228Phase 2
• Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00085124Phase 3
• S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's LymphomaTerminatedNCT00080847Phase 2
• Oblimersen in Treating Patients With Merkel Cell CarcinomaCompletedNCT00079131Phase 2
• Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301Status unknownNCT00070343Not applicable
• Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaCompletedNCT00070083Phase 1
• Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's MacroglobulinemiaCompletedNCT00062244Phase 1/2
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00059813Phase 2
• Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal CancerCompletedNCT00055822Phase 1/2
• Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid TumorsCompletedNCT00054548Phase 1
• Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00049374Phase 2
• Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
• Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00047229Phase 2
• Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00042978Phase 2
• Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid TumorsCompletedNCT00039481Phase 1
• Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00039117Phase 1
• Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung CancerStatus unknownNCT00030641Phase 2/3
• Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00024440Phase 3
• Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00017602Phase 3
• Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00017589Phase 2
• Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT00017251Phase 1
• Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant MelanomaCompletedNCT00016263Phase 3

← Oblimersen overview